Efficient Derivation of Cortical Glutamatergic Neurons from Human Pluripotent Stem Cells: A Model System to Study Neurotoxicity in Alzheimer's Disease
Neurobiology of Disease
Tandis Vazin, K. Aurelia Ball, Hui Lu, Hyungju Park, Yasaman Ataeijannati, Teresa Head-Gordon, Muming Poo, David V. Schaffer. Efficient Derivation of Cortical Glutamatergic Neurons from Human Pluripotent Stem Cells: A model System to Study Neurotoxicity in Alzheimer’s Disease. Neurobiology of Disease, 2014; 62:62-72.
Alzheimer's disease (AD) is among the most prevalent forms of dementia affecting the aging population, and pharmacological therapies to date have not been successful in preventing disease progression. Future therapeutic efforts may benefit from the development of models that enable basic investigation of early disease pathology. In particular, disease-relevant models based on human pluripotent stem cells (hPSCs) may be promising approaches to assess the impact of neurotoxic agents in AD on specific neuronal populations and thereby facilitate the development of novel interventions to avert early disease mechanisms. We implemented an efficient paradigm to convert hPSCs into enriched populations of cortical glutamatergic neurons emerging from dorsal forebrain neural progenitors, aided by modulating Sonic hedgehog (Shh) signaling. Since AD is generally known to be toxic to glutamatergic circuits, we exposed glutamatergic neurons derived from hESCs to an oligomeric pre-fibrillar forms of Aβ known as “globulomers”, which have shown strong correlation with the level of cognitive deficits in AD. Administration of such Aβ oligomers yielded signs of the disease, including cell culture age-dependent binding of Aβ and cell death in the glutamatergic populations. Furthermore, consistent with previous findings in postmortem human AD brain, Aβ-induced toxicity was selective for glutamatergic rather than GABAeric neurons present in our cultures. This in vitro model of cortical glutamatergic neurons thus offers a system for future mechanistic investigation and therapeutic development for AD pathology using human cell types specifically affected by this disease.